SKYRIZI® (risankizumab) and RINVOQ® (upadacitinib) Data Highlight Long-Term Clinical and Endoscopic Outcomes Across Inflammatory Bowel Disease (IBD) at UEGW 2026
Key Highlights
- ➤Upadacitinib CD remission reached 78.9% at 15 mg and 86.6% at 30 mg after 144 weeks
- ➤Upadacitinib CD endoscopic remission reached 47.1% at 15 mg and 64.2% at 30 mg
- ➤Risankizumab UC clinical remission reached 54.0%–73.1% at week 96 with 180mg
- ➤Risankizumab UC endoscopic remission reached 38.8%–53.5% at week 96 with 180mg
- ➤UPlift real-world study found 70.2% of evaluable CD patients achieved response within 12 weeks
- ➤ABBV-466 Phase 2a study reported endoscopic remission in moderate-to-severe Crohn's disease
Expert Statements
Sofie Berg, Therapeutic area head, immunology, international medical affairs, AbbVie
“Crohn's disease and ulcerative colitis are chronic, lifelong conditions, and understanding how patients respond to treatment over time and in everyday clinical practice is critical”
Sofie Berg, Therapeutic area head, immunology, international medical affairs, AbbVie
“The data presented at UEGW 2026 build on our growing body of evidence that can help clinicians move toward favorable long-term outcomes for people living with IBD.”
SKYRIZI® (risankizumab) and RINVOQ® (upadacitinib) Data Highlight Long-Term Clinical and Endoscopic Outcomes Across Inflammatory Bowel Disease (IBD) at UEGW 2026 PR Newswire
* 20 scientific presentations underscore the breadth of AbbVie's leadership in Inflammatory Bowel Disease (IBD) research programs * Latest long-term and real-world data with SKYRIZI(®)(risankizumab) and RINVOQ(®) (upadacitinib) provide additional insight into clinical and endoscopic outcomes over approximately three years in moderately to severely active Crohn's disease and ulcerative colitis * New data evaluating endoscopic remission with investigational dual-targeting therapy ABBV-466 in patients with moderate-to-severe Crohn's disease will also be presented NORTH CHICAGO, Ill., Oct. 17, 2026 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced the presentation of 20 new scientific abstracts from its IBD portfolio at the 2026 United European Gastroenterology (UEG) Week, October 17-20 in Barcelona, Spain. Together, the data reflect the breadth of AbbVie's research across IBD, including established therapies studied over longer treatment periods and in real-world clinical practice.
Get started
Create a free account to read the full story.